Finally, our findings provide validated novel dysregulated proteins not-previously associated with CRC and CRC metastasis, BAIAP2, GLG1, PHYHIPL, TNFRSF10A and CDKN2AIP, which should be further explored in subsequent studies to determine their usefulness as advanced CRC stage biomarkers and should be the focus of functional experiments to determine their roles in CRC formation, progression, and metastasis, to potentially identify new therapeutic targets of the disease. This evidence concerns the gene CDKN2AIP and colorectal carcinoma.